NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: 36th International Epilepsy Congress, Lisboa Congress Centre, Lisbon, PortugalDATE: August 30 – September ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancerExpands Bria-OTS+ novel personalized off-the-shelf immunotherapy platform to prostate cancer, an urgent unmet medical needPrincipal Investigator: Dr. William Oh, MD, Yale Cancer Center PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TS ...

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare ConferenceLocation: Ne ...

Company Overview - Protalix BioTherapeutics (PLX) is a commercial-stage biotech company focused on recombinant therapeutic proteins [1] - The company utilizes its proprietary plant cell-based ProCellEx technology [1] Product Portfolio - Protalix has two approved enzyme replacement therapies: 1) Elfabrio for Fabry disease 2) Elelyso for Gaucher disease [1]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **Chinese stock market** and its impact on the economy, particularly amid a growth slowdown and recent market rally since September 2024 [1][2][4]. Core Insights and Arguments 1. **Stock Market Rally Drivers**: - The Wind All A-Share Index surged by **56%** and the Hang Seng Index by **40%** since their lows in September 2024, driven by solid fundamentals, policy pivots, and a resurgence in biopharma [2][4]. - The rally is characterized by increased retail investor enthusiasm, with **6.8 million** new brokerage accounts opened in October 2024, the largest monthly increase since June 2015 [27][30]. 2. **Economic Fundamentals Weakening**: - Despite the stock market rally, economic fundamentals are expected to weaken in H2 2025 due to new austerity measures affecting mid-tier restaurants and alcohol sales, a payback effect from strong durable goods sales, and a slowdown in export growth [3][37]. - July activity data showed a decline in industrial production and retail sales growth, with industrial production dropping to **5.7%** y-o-y and retail sales to **3.7%** y-o-y [38]. 3. **Limited Boost to Real Economy**: - Historical lessons from the 2015 stock market crash suggest that the current rally may provide limited support to the real economy, with potential crowding out of big-item consumption and capital expenditure [4][61]. - The wealth effect from the stock market boom may not translate into increased consumption due to shifts in investment focus [4][61]. 4. **Beijing's Policy Strategy**: - Beijing faces a dilemma: rolling out pro-growth measures could inflate a stock market bubble, while inaction could worsen the growth slowdown. A cautious approach is recommended, avoiding high-profile monetary measures while addressing deep-rooted issues like the social security system [5][62]. - Future stimulus measures may include a **10bp cut in policy rates** and a **50bp cut in the reserve requirement ratio (RRR)** in Q4 2025, though timing remains uncertain [6][64]. 5. **Property Sector Challenges**: - The property sector continues to struggle, with new home sales and prices declining. The presales system has created a "bank run" scenario for developers, necessitating direct fiscal support from the government [65][66]. - Addressing the property sector's debt overhang is critical, with recommendations for the government to act as a "builder of last resort" to stabilize the market [67]. Other Important Insights - **AI and Biopharma as Growth Drivers**: The emergence of AI technologies, particularly the DeepSeek model, and a surge in biopharma innovations have been pivotal in driving market optimism [10][15]. - **US-China Relations**: Improved perceptions of US-China relations, particularly regarding tariffs and trade negotiations, have contributed to positive market sentiment [19][20]. - **Investor Sentiment**: The role of government media in shaping investor sentiment has been significant, with past comments contributing to market bubbles [60]. This summary encapsulates the key points discussed in the conference call, highlighting the interplay between the stock market, economic fundamentals, and policy responses in China.

Core Viewpoint - Iovance Biotherapeutics, despite its innovative drug Amtagvi for advanced melanoma, faces challenges in stock performance and operational execution [1][2]. Company Overview - Iovance Biotherapeutics is a small-cap biotech company known for developing Amtagvi, the first approved treatment for advanced melanoma [1]. - The manufacturing and administration process of Amtagvi is complex, requiring tumor samples from patients to extract T cells for lab growth, followed by patient-specific infusions [4]. Financial Performance - In Q2, Iovance reported approximately $60 million in revenue, nearly double from the previous year, primarily driven by Amtagvi sales [6]. - For fiscal 2025, the company anticipates total product revenue between $250 million and $300 million, predominantly from Amtagvi [6]. Market Potential - Amtagvi is expected to gain approval in additional regions, including Canada and Europe, within the next 12 months, potentially expanding the market significantly [7]. - The U.S. market for Amtagvi remains largely untapped, with only over 100 patients treated compared to the 8,000 annual melanoma deaths [8]. - There are opportunities for label expansions into other cancer indications, which could further increase the target market for Amtagvi [9]. Challenges - The complex and costly nature of Amtagvi poses challenges for Iovance in achieving profitability and market traction [10]. - The company ended Q2 with approximately $307 million in cash, which is projected to last until Q4 of the following year, indicating potential financial strain [11]. - Clinical and regulatory hurdles could negatively impact the stock price and overall company performance [12].

Group 1 - The FDA decision on ONS-5010 (Lytenava) is imminent, marking a critical inflection point for Outlook Therapeutics (OTLK) [1] - ONS-5010 has already been validated in Europe, indicating potential for market acceptance [1] - The focus is on identifying biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Group 2 - The analysis emphasizes the importance of evaluating the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities [1] - The biotech sector is characterized by the potential for breakthrough science to yield significant returns, necessitating careful scrutiny [1]

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/F924ACA3z3 https://t.co/TetXgntzaP ...

Core Viewpoint - A class action securities lawsuit has been filed against Altimmune, Inc. due to alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the company failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune plummeted by 53.2%, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the announcement of the trial results [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]